Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia
- PMID: 20497580
- PMCID: PMC2886045
- DOI: 10.1186/1471-2407-10-231
Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia
Abstract
Background: We evaluated if the survival benefit of adding rituximab to standard chemotherapy for non-Hodgkin lymphoma (NHL) observed in clinical trials has been experienced by an Australian NHL patient population.
Methods: NHL cases diagnosed in 1985-2004 in New South Wales (NSW) were followed-up to the end of 2004. Rituximab prescription data were obtained from Medicare Australia. Using a Poisson regression model adjusted for age group, sex, NHL subtype and time period (1990-1994, 1995-1999 and 2000-2004), we estimated excess risk of death after a diagnosis of NHL. To give context to the survival trend, trends in incidence and mortality were also estimated.
Results: Compared with 1990-1994, after adjusting for age, sex and NHL subtype the relative excess risk of death was significantly lower (p < 0.0001) in 1995-1999 (0.89) and 2000-2004 (0.74). A sharp fall in mortality was observed from 2000 to 2004 (annual percentage change (APC) = -4.7, p = 0.009), while a small but significant rise in incidence was seen from 1990 to 2004 (APC = 0.5, p = 0.01). The number of times rituximab was dispensed in NSW increased rapidly from 1274 in 1999 to 9250 in 2004.
Conclusion: It is likely that some benefit of adding rituximab to the standard chemotherapy for NHL has been experienced at the population level.
Figures



Similar articles
-
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.Leuk Lymphoma. 2005 Nov;46(11):1569-73. doi: 10.1080/10428190500217312. Leuk Lymphoma. 2005. PMID: 16236611 Clinical Trial.
-
Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.Leuk Lymphoma. 2006 Jul;47(7):1306-14. doi: 10.1080/10428190500525656. Leuk Lymphoma. 2006. PMID: 16923561 Clinical Trial.
-
Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.Semin Oncol. 2004 Feb;31(1 Suppl 2):7-11. Semin Oncol. 2004. PMID: 15042528 Review.
-
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27. Lancet Oncol. 2015. PMID: 25925619 Clinical Trial.
-
Non-Hodgkin lymphoma: an update.Lancet Oncol. 2004 Jun;5(6):341-53. doi: 10.1016/S1470-2045(04)01490-1. Lancet Oncol. 2004. PMID: 15172354 Review.
Cited by
-
Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010.Haematologica. 2015 Apr;100(4):525-33. doi: 10.3324/haematol.2014.107300. Epub 2014 Dec 15. Haematologica. 2015. PMID: 25512643 Free PMC article.
-
Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10.PLoS One. 2016 Mar 3;11(3):e0150734. doi: 10.1371/journal.pone.0150734. eCollection 2016. PLoS One. 2016. PMID: 26938056 Free PMC article.
-
Histopathological Evaluation of Angiogenic Markers in Non-Hodgkin's Lymphoma.J Lab Physicians. 2023 Jan 18;15(2):282-288. doi: 10.1055/s-0042-1760400. eCollection 2023 Jun. J Lab Physicians. 2023. PMID: 37323605 Free PMC article.
References
-
- Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002–1006. doi: 10.1056/NEJM199304083281404. - DOI - PubMed
-
- Australian Drug Evaluation Committee - 197th meeting recommendations. http://www.tga.gov.au/docs/html/adec/adec0197.htm
-
- Australian Drug Evaluation Committee - 220th meeting recommendations. http://www.tga.gov.au/docs/html/adec/adec0220.htm
-
- Tracey E, Alam N, Chen W, Bishop J. Cancer in New South Wales: Incidence and Mortality 2006. Sydney: Cancer Institute NSW; 2008.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources